KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Gains from Investment Securities (2016 - 2025)

Pfizer (PFE) has disclosed Gains from Investment Securities for 17 consecutive years, with $590.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 67.31% to $590.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $288.0 million, a 87.26% decrease, with the full-year FY2025 number at $288.0 million, down 87.26% from a year prior.
  • Gains from Investment Securities was $590.0 million for Q4 2025 at Pfizer, up from -$3.8 billion in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $4.9 billion in Q4 2022 to a low of -$3.8 billion in Q3 2025.
  • A 5-year average of $687.1 million and a median of $341.5 million in 2022 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 20950.0% in 2024; the steepest drop was 622.48% in 2024.
  • Pfizer's Gains from Investment Securities stood at $1.6 billion in 2021, then soared by 216.95% to $4.9 billion in 2022, then tumbled by 111.49% to -$565.0 million in 2023, then soared by 419.47% to $1.8 billion in 2024, then plummeted by 67.31% to $590.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Gains from Investment Securities are $590.0 million (Q4 2025), -$3.8 billion (Q3 2025), and $3.3 billion (Q2 2025).